Diffuse anterior scleritis during OKT3 monoclonal antibody therapy for renal transplant rejection.
OKT3, a murine monoclonal antibody, is a potent, specific immunosuppressive agent used in solid-organ transplantation both as an adjunct during induction therapy and for treatment of steroid-resistant graft rejection. Minor, self-limiting ocular complications are often seen with this drug, of which conjunctivitis is the most common, occurring in approximately three-quarters of patients. We describe the more serious and previously unreported complication of diffuse anterior scleritis, which developed on the fifth day of OKT3 therapy in a 47-year-old man who had undergone cadaveric renal transplantation. Despite continuation of OKT3 treatment the scleritis resolved rapidly with increased dosages of prednisone.
McCarthy
J M
JM
Department of Medicine, Vancouver General Hospital, University of British Columbia.
Sullivan
K
K
Keown
P A
PA
Rollins
D T
DT
D005938:Glucocorticoids / Q000627:therapeutic use; D006084:Graft Rejection; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D015423:Scleritis / Q000188:drug therapy / Q000209:etiology*
D005938:Glucocorticoids; D016853:Muromonab-CD3; D011239:Prednisolone